| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 46 | 2025 | 975 | 12.870 |
Why?
|
| Pre-Exposure Prophylaxis | 19 | 2025 | 187 | 8.190 |
Why?
|
| Anti-HIV Agents | 19 | 2025 | 199 | 6.600 |
Why?
|
| Emergency Service, Hospital | 10 | 2024 | 594 | 2.590 |
Why?
|
| Electronic Health Records | 7 | 2024 | 385 | 2.440 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 250 | 2.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 570 | 1.760 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 334 | 1.480 |
Why?
|
| Health Personnel | 4 | 2025 | 241 | 1.470 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 296 | 1.390 |
Why?
|
| Chicago | 16 | 2024 | 1504 | 1.380 |
Why?
|
| Betacoronavirus | 4 | 2020 | 283 | 1.300 |
Why?
|
| Medical Informatics | 2 | 2021 | 51 | 1.260 |
Why?
|
| Clostridium Infections | 2 | 2023 | 128 | 1.250 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 332 | 1.220 |
Why?
|
| Ambulatory Care Facilities | 5 | 2023 | 118 | 1.210 |
Why?
|
| Humans | 79 | 2025 | 95991 | 1.190 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 60 | 1.180 |
Why?
|
| Telemedicine | 2 | 2022 | 230 | 1.170 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 346 | 1.140 |
Why?
|
| Adult | 39 | 2025 | 28638 | 1.140 |
Why?
|
| Female | 47 | 2025 | 49948 | 1.060 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 111 | 1.020 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 58 | 0.940 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 43 | 0.920 |
Why?
|
| Middle Aged | 33 | 2025 | 28256 | 0.910 |
Why?
|
| Pandemics | 11 | 2022 | 881 | 0.910 |
Why?
|
| Academic Medical Centers | 3 | 2025 | 421 | 0.890 |
Why?
|
| AIDS Serodiagnosis | 3 | 2022 | 27 | 0.860 |
Why?
|
| Contact Tracing | 2 | 2021 | 29 | 0.830 |
Why?
|
| Algorithms | 5 | 2024 | 2011 | 0.830 |
Why?
|
| Male | 39 | 2025 | 45739 | 0.820 |
Why?
|
| Natural Language Processing | 2 | 2021 | 45 | 0.820 |
Why?
|
| Sexual Partners | 3 | 2024 | 106 | 0.810 |
Why?
|
| Risk Assessment | 3 | 2020 | 2478 | 0.800 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 80 | 0.780 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 38 | 0.780 |
Why?
|
| Influenza, Human | 2 | 2016 | 370 | 0.760 |
Why?
|
| Antimicrobial Stewardship | 2 | 2021 | 24 | 0.730 |
Why?
|
| Hepatitis C | 1 | 2023 | 185 | 0.690 |
Why?
|
| United States | 13 | 2024 | 7762 | 0.670 |
Why?
|
| Hospitalization | 5 | 2022 | 949 | 0.660 |
Why?
|
| Virus Shedding | 1 | 2020 | 29 | 0.660 |
Why?
|
| Viral Load | 4 | 2024 | 165 | 0.660 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 10 | 0.650 |
Why?
|
| Ambulatory Care | 2 | 2023 | 200 | 0.640 |
Why?
|
| Retrospective Studies | 20 | 2024 | 10191 | 0.640 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 126 | 0.630 |
Why?
|
| Continuity of Patient Care | 4 | 2024 | 180 | 0.630 |
Why?
|
| Respiratory System | 1 | 2020 | 121 | 0.620 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.620 |
Why?
|
| Qualitative Research | 4 | 2024 | 362 | 0.610 |
Why?
|
| Patient Compliance | 1 | 2021 | 239 | 0.610 |
Why?
|
| HIV-1 | 1 | 2020 | 181 | 0.610 |
Why?
|
| RNA, Viral | 1 | 2020 | 311 | 0.600 |
Why?
|
| Infection Control | 1 | 2020 | 132 | 0.600 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 14 | 0.590 |
Why?
|
| Heterosexuality | 1 | 2018 | 21 | 0.580 |
Why?
|
| Travel | 1 | 2018 | 72 | 0.560 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 82 | 0.550 |
Why?
|
| Antifungal Agents | 3 | 2017 | 126 | 0.540 |
Why?
|
| Cross Infection | 2 | 2016 | 159 | 0.540 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.530 |
Why?
|
| Coinfection | 4 | 2021 | 67 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 850 | 0.530 |
Why?
|
| Itraconazole | 1 | 2016 | 12 | 0.510 |
Why?
|
| Violence | 1 | 2018 | 154 | 0.510 |
Why?
|
| Residence Characteristics | 1 | 2018 | 213 | 0.510 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 39 | 0.500 |
Why?
|
| Sorbitol | 1 | 2016 | 9 | 0.490 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 9 | 0.490 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 67 | 0.490 |
Why?
|
| Focus Groups | 3 | 2025 | 191 | 0.470 |
Why?
|
| Population Surveillance | 1 | 2016 | 218 | 0.470 |
Why?
|
| Automation | 1 | 2016 | 114 | 0.470 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 157 | 0.460 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 22 | 0.440 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 38 | 0.440 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 155 | 0.440 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 52 | 0.430 |
Why?
|
| Hospitals | 1 | 2016 | 330 | 0.420 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 173 | 0.410 |
Why?
|
| Machine Learning | 3 | 2022 | 350 | 0.400 |
Why?
|
| Young Adult | 11 | 2025 | 7002 | 0.400 |
Why?
|
| Logistic Models | 3 | 2022 | 1263 | 0.380 |
Why?
|
| Candida | 3 | 2017 | 20 | 0.380 |
Why?
|
| Candidiasis | 3 | 2017 | 39 | 0.380 |
Why?
|
| Mass Screening | 5 | 2024 | 713 | 0.360 |
Why?
|
| Sepsis | 1 | 2016 | 391 | 0.350 |
Why?
|
| Risk Factors | 6 | 2023 | 5949 | 0.350 |
Why?
|
| Comorbidity | 4 | 2023 | 1006 | 0.350 |
Why?
|
| Time Factors | 5 | 2022 | 5578 | 0.350 |
Why?
|
| Electronics | 2 | 2021 | 20 | 0.350 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 286 | 0.340 |
Why?
|
| Cities | 2 | 2021 | 57 | 0.330 |
Why?
|
| Soft Tissue Infections | 2 | 2021 | 27 | 0.330 |
Why?
|
| Vaccination | 2 | 2022 | 311 | 0.320 |
Why?
|
| Syphilis | 2 | 2021 | 36 | 0.310 |
Why?
|
| Inpatients | 3 | 2021 | 347 | 0.310 |
Why?
|
| Adolescent | 10 | 2025 | 9889 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 154 | 0.290 |
Why?
|
| Family Planning Services | 2 | 2025 | 47 | 0.270 |
Why?
|
| Models, Theoretical | 2 | 2021 | 503 | 0.270 |
Why?
|
| Aged | 14 | 2021 | 20878 | 0.270 |
Why?
|
| Urban Population | 2 | 2018 | 240 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2024 | 936 | 0.260 |
Why?
|
| Survival Analysis | 2 | 2022 | 1536 | 0.240 |
Why?
|
| Medicare | 2 | 2020 | 455 | 0.240 |
Why?
|
| Epidemics | 1 | 2025 | 41 | 0.230 |
Why?
|
| Community-Acquired Infections | 2 | 2021 | 66 | 0.220 |
Why?
|
| Patient Portals | 1 | 2024 | 24 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 74 | 0.200 |
Why?
|
| Program Evaluation | 1 | 2024 | 325 | 0.190 |
Why?
|
| Age Factors | 2 | 2018 | 1963 | 0.190 |
Why?
|
| Social Support | 1 | 2024 | 239 | 0.190 |
Why?
|
| Safe Sex | 2 | 2020 | 24 | 0.190 |
Why?
|
| Social Media | 1 | 2024 | 111 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2021 | 4663 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2024 | 819 | 0.180 |
Why?
|
| Anxiety | 1 | 2024 | 339 | 0.180 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2021 | 25 | 0.180 |
Why?
|
| HIV | 1 | 2021 | 49 | 0.170 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 65 | 0.170 |
Why?
|
| Minority Groups | 1 | 2022 | 155 | 0.170 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 15 | 0.170 |
Why?
|
| Demography | 1 | 2021 | 189 | 0.170 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.170 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 11 | 0.170 |
Why?
|
| Azithromycin | 1 | 2020 | 17 | 0.170 |
Why?
|
| Drug Resistance, Multiple, Fungal | 2 | 2017 | 3 | 0.160 |
Why?
|
| Cephalosporins | 1 | 2020 | 25 | 0.160 |
Why?
|
| Postal Service | 1 | 2020 | 23 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.160 |
Why?
|
| Social Networking | 1 | 2021 | 85 | 0.160 |
Why?
|
| Critical Illness | 1 | 2023 | 347 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 74 | 0.160 |
Why?
|
| Depression | 1 | 2024 | 560 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 649 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1875 | 0.160 |
Why?
|
| Bias | 1 | 2020 | 139 | 0.150 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 9 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 683 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 490 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 937 | 0.150 |
Why?
|
| Condoms | 1 | 2019 | 39 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 284 | 0.150 |
Why?
|
| Geographic Information Systems | 1 | 2018 | 28 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 14 | 0.150 |
Why?
|
| Illinois | 1 | 2020 | 531 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 898 | 0.140 |
Why?
|
| Crime | 1 | 2018 | 38 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2018 | 174 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2024 | 850 | 0.140 |
Why?
|
| Risk-Taking | 1 | 2019 | 163 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2020 | 481 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 185 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2018 | 375 | 0.130 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 18 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2020 | 298 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2093 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2016 | 71 | 0.120 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2016 | 28 | 0.120 |
Why?
|
| Penicillins | 1 | 2016 | 24 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 40 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1957 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2864 | 0.120 |
Why?
|
| Seasons | 1 | 2016 | 246 | 0.120 |
Why?
|
| Medicaid | 1 | 2018 | 259 | 0.120 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 25 | 0.120 |
Why?
|
| Sexual Behavior | 1 | 2018 | 334 | 0.110 |
Why?
|
| France | 2 | 2025 | 54 | 0.110 |
Why?
|
| Nasopharynx | 1 | 2015 | 51 | 0.110 |
Why?
|
| Bacteriuria | 1 | 2014 | 10 | 0.110 |
Why?
|
| Pneumonia | 1 | 2016 | 198 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 75 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 252 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 84 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2040 | 0.100 |
Why?
|
| Infant | 2 | 2019 | 3367 | 0.100 |
Why?
|
| Obesity | 1 | 2020 | 1038 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2019 | 3977 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 930 | 0.100 |
Why?
|
| Child | 3 | 2020 | 7625 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 7206 | 0.090 |
Why?
|
| Trust | 2 | 2023 | 101 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 880 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 900 | 0.090 |
Why?
|
| Social Stigma | 2 | 2022 | 87 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2014 | 460 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1981 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 185 | 0.080 |
Why?
|
| Bacteria | 1 | 2014 | 517 | 0.080 |
Why?
|
| Seroepidemiologic Studies | 2 | 2019 | 57 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1999 | 185 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2020 | 9092 | 0.060 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2017 | 13 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 1345 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2016 | 302 | 0.060 |
Why?
|
| Global Health | 2 | 2017 | 213 | 0.060 |
Why?
|
| Urinary Tract Infections | 2 | 2014 | 84 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 35 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 30 | 0.040 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 106 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 472 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 27 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2020 | 40 | 0.040 |
Why?
|
| Patient Participation | 1 | 2022 | 244 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 192 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 639 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1999 | 54 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 1999 | 10 | 0.040 |
Why?
|
| Synovial Membrane | 1 | 1999 | 31 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 157 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 669 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 711 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2021 | 132 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 180 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 287 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1216 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1999 | 3635 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 132 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 25 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2016 | 61 | 0.030 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 72 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 129 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 89 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1132 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1994 | 25 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 56 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 30 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1705 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1096 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1994 | 148 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 909 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2613 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1994 | 457 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 4024 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 75 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 152 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1382 | 0.020 |
Why?
|
| Contrast Media | 1 | 1994 | 1095 | 0.020 |
Why?
|
| Gadolinium DTPA | 2 | 1999 | 255 | 0.020 |
Why?
|
| Bone Cysts | 1 | 1999 | 8 | 0.010 |
Why?
|
| Synovitis | 1 | 1999 | 15 | 0.010 |
Why?
|
| Finger Joint | 1 | 1999 | 13 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 813 | 0.010 |
Why?
|
| Laminectomy | 1 | 1994 | 42 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1994 | 300 | 0.010 |
Why?
|